460 related articles for article (PubMed ID: 11793023)
21. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
[TBL] [Abstract][Full Text] [Related]
22. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes.
Gastaldelli A; Miyazaki Y; Pettiti M; Santini E; Ciociaro D; Defronzo RA; Ferrannini E
J Clin Endocrinol Metab; 2006 Mar; 91(3):806-12. PubMed ID: 16352689
[TBL] [Abstract][Full Text] [Related]
23. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
[TBL] [Abstract][Full Text] [Related]
24. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
Juhl CB; Hollingdal M; Pørksen N; Prange A; Lönnqvist F; Schmitz O
J Clin Endocrinol Metab; 2003 Aug; 88(8):3794-800. PubMed ID: 12915671
[TBL] [Abstract][Full Text] [Related]
25. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Bajaj M; Suraamornkul S; Pratipanawatr T; Hardies LJ; Pratipanawatr W; Glass L; Cersosimo E; Miyazaki Y; DeFronzo RA
Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
[TBL] [Abstract][Full Text] [Related]
26. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
27. Decreased susceptibility to fatty acid-induced peripheral tissue insulin resistance in women.
Frias JP; Macaraeg GB; Ofrecio J; Yu JG; Olefsky JM; Kruszynska YT
Diabetes; 2001 Jun; 50(6):1344-50. PubMed ID: 11375335
[TBL] [Abstract][Full Text] [Related]
28. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
Bajaj M; Suraamornkul S; Kashyap S; Cusi K; Mandarino L; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
[TBL] [Abstract][Full Text] [Related]
29. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
[TBL] [Abstract][Full Text] [Related]
30. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
31. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
32. Production and metabolic clearance of glucose under basal conditions in Type II (non-insulin-dependent) diabetes mellitus.
Radziuk J; Pye S
Diabetologia; 2001 Aug; 44(8):983-91. PubMed ID: 11484075
[TBL] [Abstract][Full Text] [Related]
33. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
34. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
Suter SL; Nolan JJ; Wallace P; Gumbiner B; Olefsky JM
Diabetes Care; 1992 Feb; 15(2):193-203. PubMed ID: 1547676
[TBL] [Abstract][Full Text] [Related]
35. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
Raskin P; Rappaport EB; Cole ST; Yan Y; Patwardhan R; Freed MI
Diabetologia; 2000 Mar; 43(3):278-84. PubMed ID: 10768088
[TBL] [Abstract][Full Text] [Related]
36. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
[TBL] [Abstract][Full Text] [Related]
37. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
38. Suppression of non-esterified fatty acid concentrations by insulin in patients with hypertension.
Sheu WH; Jeng CY; Shieh SM; Fuh MM
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Dec; 56(6):367-72. PubMed ID: 8851476
[TBL] [Abstract][Full Text] [Related]
39. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Yokoyama I; Yonekura K; Moritan T; Tateno M; Momose T; Ohtomo K; Inoue Y; Nagai R
J Nucl Med; 2001 Jul; 42(7):1005-10. PubMed ID: 11438619
[TBL] [Abstract][Full Text] [Related]
40. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
Chen XM; Zhang WQ; Tian Y; Wang LF; Chen CC; Qiu CM
Cardiovasc Diabetol; 2018 Apr; 17(1):53. PubMed ID: 29636047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
